These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 12860911)

  • 21. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
    Lakka HM; Laaksonen DE; Lakka TA; Niskanen LK; Kumpusalo E; Tuomilehto J; Salonen JT
    JAMA; 2002 Dec; 288(21):2709-16. PubMed ID: 12460094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study.
    Kabootari M; Asgari S; Mansournia MA; Khalili D; Valizadeh M; Azizi F; Hadaegh F
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes.
    Blaha MJ; Gebretsadik T; Shintani A; Elasy TA
    Obesity (Silver Spring); 2008 Apr; 16(4):869-74. PubMed ID: 18277389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]).
    Tehrani DM; Zhao Y; Blaha MJ; Mora S; Mackey RH; Michos ED; Budoff MJ; Cromwell W; Otvos JD; Rosenblit PD; Wong ND
    Am J Cardiol; 2016 Jun; 117(12):1921-7. PubMed ID: 27156827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study.
    Lawlor DA; Smith GD; Ebrahim S
    Diabetologia; 2006 Jan; 49(1):41-8. PubMed ID: 16378165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.
    Lorenzo C; Williams K; Hunt KJ; Haffner SM
    Diabetes Care; 2007 Jan; 30(1):8-13. PubMed ID: 17192325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
    Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
    White HD; Tonkin A; Simes J; Stewart R; Mann K; Thompson P; Colquhoun D; West M; Nestel P; Sullivan D; Keech AC; Hunt D; Blankenberg S;
    J Am Coll Cardiol; 2014 Feb; 63(4):345-54. PubMed ID: 24140630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
    Miller M; Cannon CP; Murphy SA; Qin J; Ray KK; Braunwald E;
    J Am Coll Cardiol; 2008 Feb; 51(7):724-30. PubMed ID: 18279736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly.
    Vinluan CM; Zreikat HH; Levy JR; Cheang KI
    Metabolism; 2012 Mar; 61(3):302-9. PubMed ID: 21840552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities.
    Wildman RP; McGinn AP; Lin J; Wang D; Muntner P; Cohen HW; Reynolds K; Fonseca V; Sowers MR
    Obesity (Silver Spring); 2011 Apr; 19(4):853-60. PubMed ID: 20725064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease.
    Ford I; Shah AS; Zhang R; McAllister DA; Strachan FE; Caslake M; Newby DE; Packard CJ; Mills NL
    J Am Coll Cardiol; 2016 Dec; 68(25):2719-2728. PubMed ID: 28007133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease.
    Natarajan S; Liao Y; Cao G; Lipsitz SR; McGee DL
    Arch Intern Med; 2003 Jul; 163(14):1735-40. PubMed ID: 12885690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-1992 and 1997-1999 despite more central obesity.
    Lorenzo C; Williams K; Gonzalez-Villalpando C; Haffner SM
    Diabetes Care; 2005 Oct; 28(10):2480-5. PubMed ID: 16186283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role?
    Wannamethee SG; Shaper AG; Whincup PH; Lennon L; Sattar N
    J Am Coll Cardiol; 2011 Oct; 58(18):1870-7. PubMed ID: 22018297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults.
    Onat A; Can G; Çiçek G; Ayhan E; Doğan Y; Kaya H
    Acta Diabetol; 2013 Aug; 50(4):519-28. PubMed ID: 21769500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.
    Aguilar D; Fisher MR; O'Connor CM; Dunne MW; Muhlestein JB; Yao L; Gupta S; Benner RJ; Cook TD; Edwards D; Pfeffer MA;
    Am Heart J; 2006 Aug; 152(2):298-304. PubMed ID: 16875914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.
    Onat A; Ceyhan K; Başar O; Erer B; Toprak S; Sansoy V
    Atherosclerosis; 2002 Dec; 165(2):285-92. PubMed ID: 12417279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.
    Correll CU; Frederickson AM; Kane JM; Manu P
    J Clin Psychiatry; 2006 Apr; 67(4):575-83. PubMed ID: 16669722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.